IDEXX Laboratories (FRA:IX1) Beginning Cash Position: €156 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IX1 IDEXX Laboratories Inc FRA:IX1
97 GF Score
Price €484.00
GF Value €532.62
Valuation Fairly Valued
View Full Analysis

What is IDEXX Laboratories Beginning Cash Position?

IDEXX Laboratories FRA:IX1 +2.80% 97 Beginning Cash Position is €156 Mil as of Mar. 2026. GuruFocus rates FRA:IX1 with a GF Score™ of 97/100 and a GF Value™ of €532.62 (Fairly Valued).

IDEXX Laboratories's Beginning Cash Position for the quarter that ended in Mar. 2026 was €156 Mil.

IDEXX Laboratories's quarterly Beginning Cash Position increased from Sep. 2025 (€140 Mil) to Dec. 2025 (€178 Mil) but then declined from Dec. 2025 (€178 Mil) to Mar. 2026 (€156 Mil).

IDEXX Laboratories's annual Beginning Cash Position increased from Dec. 2023 (€103 Mil) to Dec. 2024 (€434 Mil) but then declined from Dec. 2024 (€434 Mil) to Dec. 2025 (€246 Mil).

IDEXX Laboratories Beginning Cash Position Related Terms

IDEXX Laboratories Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for IDEXX Laboratories's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEXX Laboratories Beginning Cash Position Chart

IDEXX Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 339.78 136.36 103.20 433.51 246.18

IDEXX Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 266.65 142.16 140.23 177.77 155.76
FRA:IX1
97GF Score
IDEXX Laboratories Inc FRA:IX1
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDEXX Laboratories Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €156 Mil mean?
IDEXX Laboratories (FRA:IX1) has a Beginning Cash Position of €156 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on IDEXX Laboratories and its competitors.
Is IDEXX Laboratories' Beginning Cash Position too high?
IDEXX Laboratories' current Beginning Cash Position is €156 Mil. Overall, IDEXX Laboratories has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Beginning Cash Position compare to A and NTRA?
IDEXX Laboratories' Beginning Cash Position of €156 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Diagnostics & Research company?
A good Beginning Cash Position depends on the Medical Diagnostics & Research industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on IDEXX Laboratories and its competitors. IDEXX Laboratories's current Beginning Cash Position is €156 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Fairly Valued. The stock's GF Value™ is €532.62, compared to a current price of €484.00 — trading 9.1% below its estimated fair value. The current Beginning Cash Position is €156 Mil. IDEXX Laboratories' overall GF Score™ is 97/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current Beginning Cash Position is €156 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?

Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued. The current stock price of €484.00 is trading 9.1% below its estimated GF Value™ of €532.62. GuruFocus considers IDEXX Laboratories to be Fairly Valued.

Key valuation signals for FRA:IX1:

  • Beginning Cash Position: €156 Mil
  • GF Value™: €532.62 vs. price of €484.00 (9.1% below fair value)
  • GF Score™: 97/100

No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IDEXX Laboratories Business Description

Address One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
97GF Score

Get the complete analysis for FRA:IX1

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€484.00
Price
€532.62
GF Value